Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 4/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL623920 | 1.00 | — | — | |
| SCHEMBL472132 | 1.00 | CXCR4 (0.89) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL11232630 | 1.00 | CXCR4 (0.89) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL11235838 | 1.00 | CXCR4 (0.89) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL577659 | 0.94 | CXCR4 (1.00) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL576838 | 0.94 | CXCR4 (1.00) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL3632859 | 0.94 | CXCR4 (0.80) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL22199 | 0.94 | CXCR4 (1.00) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL9947670 | 0.94 | CXCR4 (1.00) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL8503965 | 0.94 | CXCR4 (1.00) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559704-B2 | Microelectronic device cleaning composition | ENTEGRIS, INC. (US) | 2026-02-24 | — | — | US | claimed |
| US-20250295790-A1 | LECTIN-TARGETING CONJUGATES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2025-09-25 | — | — | US | claimed |
| US-20250277171-A1 | COMPOSITION FOR POST-CMP CLEANING | ENTEGRIS, INC. | 2025-09-04 | — | — | US | claimed |
| EP-4561995-A1 | 1,4-BIS-(2-HYDROXY-BENZYL)-1,4,7-TRIAZACYCLONONANE DERIVATIVES AND SIMILAR COMPOUNDS AS LIGANDS IN IRON(III) COMPLEXES FOR USE AS MRI CONTRAST AGENTS | Bracco Imaging SPA (IT) | 2025-06-04 | — | — | EP | claimed |
| CN-120037787-A | Preparation method of high-magnesium-lithium selective nanofiltration membrane | 万华化学集团股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-119565397-A | High-flux high-chemical-resistance composite nanofiltration membrane and preparation method and application thereof | 万华化学集团股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| EP-4493664-A1 | MICROELECTRONIC DEVICE CLEANING COMPOSITION | Entegris, Inc. (US) | 2025-01-22 | — | — | EP | claimed |
| CN-119343336-A | 1, 4-Bis- (2-hydroxy-benzyl) -1,4, 7-triazacyclononane derivatives and similar compounds as ligands in iron (III) complexes for use as MRI contrast agents | 伯拉考成像股份公司 | 2025-01-21 | — | — | CN | claimed |
| CN-118749809-B | Semi-absorbent cotton quilt core capable of being washed by water | 宁波博洋家纺集团有限公司 | 2024-12-27 | — | — | CN | claimed |
| EP-4444355-A2 | LECTIN-TARGETING CONJUGATES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-10-16 | — | — | EP | claimed |
| US-5681543-A | Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI | SHERING AKTIENGESELLSCHAFT (DE) | 1997-10-28 | — | — | US | claimed |
| US-5650136-A | Cascade polymer bound complexing compounds, their complexes and conjugates, processes for their production, and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-07-22 | — | — | US | claimed |
| US-5643780-A | CONTROLLING PROTEIN EXPRESSION IN CELLS | ISIS PHARMACEUTICALS, INC. (US) | 1997-07-01 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-5275801-A | X-ray and magnetic resonance imaging of tumors | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-01-04 | — | — | US | claimed |
| EP-0531447-A4 | COMPOSITIONS AND METHODS FOR MODULATING RNA ACTIVITY THROUGH MODIFICATION OF THE 5' CAP STRUCTURE OF RNA | — | 1993-08-11 | — | — | EP | claimed |
| EP-0531447-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA ACTIVITY THROUGH MODIFICATION OF THE 5' CAP STRUCTURE OF RNA | ISIS PHARMACEUTICALS, INC. (US) | 1993-03-17 | — | — | EP | claimed |
| WO-1991017755-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA ACTIVITY THROUGH MODIFICATION OF THE 5' CAP STRUCTURE OF RNA | ISIS PHARMACEUTICALS, INC. (US) | 1991-11-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295790-A1 | LECTIN-TARGETING CONJUGATES | MASP2, LGALS3BP, LGALS1 | CXCR4 2275/4885SMN1; SMN2 4554/4885ALDH1A1 3861/4885 |
| US-12559704-B2 | Microelectronic device cleaning composition | HCN1, KCNH3, ADH1C | CXCR4 1887/4885SMN1; SMN2 2432/4885ALDH1A1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.